<DOC>
	<DOCNO>NCT00774644</DOCNO>
	<brief_summary>The objective study compare relative bioavailability clarithromycin 500 mg tablet ( Ranbaxy Laboratories Limited ) BIAXIN® 500 mg tablet healthy , adult subject fast condition .</brief_summary>
	<brief_title>Bioequivalence Study Clarithromycin 500mg Tablets Under Fasting Conditions .</brief_title>
	<detailed_description>The study conduct open label , balance , randomise , two-treatment , two-period , two-sequence , single-dose , crossover , bioavailability study clarithromycin formulation compare clarithromycin 500mg tablet Ranbaxy Laboratories Biaxin® tablet 500mg ( contain clarithromycin 500 mg ) healthy , adult , human , male subject fast condition Eligible subject underwent pre-study examination include physical examination , 12-lead ECG , laboratory test - include hematology , blood chemistry , urinalysis , infectious disease ( Hepatitis B , Hepatitis Ci HIV ) , urine drug abuse . Laboratory test female subject also include serum pregnancy test .</detailed_description>
	<mesh_term>Clarithromycin</mesh_term>
	<criteria>Source Subjects : Noninstitutionalized subject consist member community large . Characterization Study Group : 1 . All subject select study least 18 year age . 2 . Female subject must unable become pregnant ( postmenopausal least 1 year , surgically sterile ) . Each subject shall give general physical examination within 28 day initiation study . Such examination include , limited , blood pressure , general observation , history . Each female subject give serum pregnancy test part prestudy screen process . At end study , subject exit evaluation consist interim history , global evaluation , clinical laboratory measurement . Adequate blood urine sample obtain within 28 day begin first period end trial clinical laboratory measurement . Clinical laboratory measurement include follow : Hematology : hemoglobin , hematocrit , red blood cell count , platelet , white blood cell count ( differential ) . Subjects history chronic alcohol consumption ( past 2 year ) , drug addiction , serious gastrointestinal , renal , hepatic cardiovascular disease , tuberculosis , epilepsy , asthma ( past 5 year ) , diabetes , psychosis glaucoma eligible study . Subjects whose clinical laboratory test value great 20 % outside normal range may retested . If clinical value outside range retesting , subject eligible participate study unless clinical investigator deem result significant . Subjects history allergic response class drug test ( include penicillin product ) exclude study . All subject urine sample assay presence drug abuse part clinical laboratory screening procedure checkin study period . Subjects find urine concentration test drug allow participate . Subjects donate blood and/or plasma least thirty ( 30 ) day prior first dose study . Subjects take investigational drag within thirty ( 30 ) day prior first dose study allow participate . Female subject pregnant able ( woman child bear potential ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2008</verification_date>
</DOC>